Pharvaris (PHVS) Cash from Financing Activities (2020 - 2026)
Pharvaris (PHVS) posted Cash from Financing Activities of -$72017.2 for Q1 2026, down 122.79% on a QoQ basis from $316027.3 in Q4 2025, and up 9.25% year-over-year from -$65917.1 in Q1 2025.
Pharvaris (PHVS) Cash from Financing Activities (2020 - 2026) Analysis & Trends
Pharvaris' Cash from Financing Activities history runs 7 years deep, the most recent figure standing at -$72017.2 for Q1 2026.
- Quarterly Cash from Financing Activities rose 9.25% year-over-year to -$72017.2 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $187.8 million (up 9464.31% YoY) and the FY2025 annual result came in at $181.5 million, up 6163.71% from the prior year.
- Cash from Financing Activities was -$72017.2 for Q1 2026 at Pharvaris, down from $316027.3 in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $69456.2 billion in Q2 2023 and bottomed at -$69434.8 billion in Q3 2023.
- A 5-year average of $1.3 billion and a median of $316027.3 in 2025 frame the typical range for Cash from Financing Activities.
- Peak annual rise in Cash from Financing Activities reached 728626264.9% in 2023, while the deepest fall reached 524286449879.51% in 2023.
- Pharvaris' Cash from Financing Activities stood at -$163045.7 in 2022, then soared by 172816.54% to $281.6 million in 2023, then sank by 99.79% to $604998.1 in 2024, then plunged by 47.76% to $316027.3 in 2025, then tumbled by 122.79% to -$72017.2 in 2026.
- Business Quant data shows PHVS's Cash from Financing Activities at -$72017.2 in Q1 2026, $316027.3 in Q4 2025, and $187.6 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,102.16 Bn | 67,101.87 Bn | - | 30.14 Mn |
| 2 | Nanobiotix | 1,909.44 Bn | 1,909.38 Bn | - | - |
| 3 | Akari Therapeutics | 989.71 Bn | 989.71 Bn | - | 53,000.00 |
| 4 | BeOne Medicines | 471.58 Bn | 466.79 Bn | 1.35 Bn | 68.63 Mn |
| 5 | Vertex Pharmaceuticals | 121.97 Bn | 114.72 Bn | 2.59 Bn | -538.80 Mn |
| 6 | Regeneron Pharmaceuticals | 69.93 Bn | 61.18 Bn | 3.31 Bn | -802.20 Mn |
| 7 | Belite Bio | 62.68 Bn | 62.68 Bn | - | - |
| 8 | Argenx Se | 55.80 Bn | 50.61 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.37 Bn | 34.36 Bn | 959.66 Mn | 15.71 Mn |
| 10 | Pharvaris | 2.22 Bn | 1.93 Bn | - | -72,017.25 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -72,017.25 |
| Mar 31, 2026 | -72,017.25 |
| Dec 31, 2025 | 316,027.34 |
| Dec 31, 2025 | 316,027.34 |
| Sep 30, 2025 | 187.56 Mn |
| Sep 30, 2025 | 187.56 Mn |
| Jun 30, 2025 | -25,921.88 |
| Jun 30, 2025 | -25,921.88 |
| Mar 31, 2025 | -79,361.53 |
| Mar 31, 2025 | -79,361.53 |
| Dec 31, 2024 | 604,998.11 |
| Dec 31, 2024 | 604,998.11 |
| Sep 30, 2024 | 1.09 Mn |
| Sep 30, 2024 | 1.09 Mn |
| Jun 30, 2024 | 348,291.29 |
| Jun 30, 2024 | 348,291.29 |
| Mar 31, 2024 | 863,703.23 |
| Mar 31, 2024 | 863,703.23 |
| Dec 31, 2023 | 281.61 Mn |
| Dec 31, 2023 | 281.61 Mn |